It’s same-store sales. It’s getting the average physician instead of doing 12 of these things a year to do 24 of them a year. I mean that’s how we double our business. It’s not about going out and finding another 2,000 doctors who want to dabble with sacral neuromodulation. This is about getting the people that know what they’re doing, giving them better products, easier tools, better support, and just getting them to talk more about it and I think if sounds quite simple. And in one respect, it really is, but once again requires real keen focus and execution.
Chris Pasquale: Great, thanks, Ray.
Raymond Cohen: Yeah. Thank you.
Operator: Thank you. Our next question comes from the line of Cecilia Furlong with Morgan Stanley. Your line is now open.
Cecilia Furlong: All right, great. Good afternoon and thanks for taking the questions. I wanted to follow-up just on some of your comments around the phenomenon OUS markets realizing Australia and the framework that you put around that, could you one for Australia just kind frame the opportunity what market is today on a relative basis versus how do you think about growth beyond ’23 and then for ’23 specifically in Europe, in other locations where you’re benefiting now from Bulkamid presence, how we should think about SNM growth in those regions?
Dan Dearen: I mean, at a high level as Ray – this is Dan. Hi, Cecilia, nice to hear you. As Ray mentioned in his prepared remarks, the Australian market for SNM we estimated around $15 million per year and we have approvals and we have coverage, but we don’t have it yet on our F15 recharge free product, which is why the statement that was made is we expect to do between $1 million and $1.5 million revenue in 2023. Now beyond that, look, we intend like we do in all markets to be the market leader, it’s just a question of perseverance in time and we don’t want to put a specific date on that. But look, as we continue to grow, the market is so heavily skewed towards the United States for all of these products that even though we will increase our OUS sales in both product categories for SNM and also for Bulkamid, the U.S. growth is going to help drive it.
And so this will probably forever be a story about the U.S. market, but our goal continues to be the market leader and as a global player as we want to take care of patients, physicians, and their practices worldwide. And so that’s why we continue these efforts, OUS. We, of course, make revenue and margin off of it, but just as being a good corporate citizen in treating patients, it’s part of the plan, and we started in Europe and we’ve worked with a number of these physicians and our previous company, we were in Australia in a big way and so it’s kind of natural for us to also move into this market since we have the full product line and we have the approvals.
Raymond Cohen: I would add two things to your question and that is that the markets outside the United States were all capitated and that’s the fundamental issue here. If there was always a fair market, we’d be on it hard, but it’s not the case. And I’ve mentioned this many times before if you take a market like the U.K., as an example, which probably one of the largest markets if not the largest market in Europe. The government is going to pay for 800 implants. So right now, you’ve got two companies fighting each other to get the lion’s share of that business and how much energy do you really want to spend in trying to grow that business when, in fact, the state of Mississippi outsailed the country of the United Kingdom, right, so you can imagine, it’s a lot easier for us to expand our efforts in Mississippi than it is in throughout the U.K. So hopefully that gives you some context why we’re so focused on the U.S. market and there is a correlation of course between having Bulkamid available in some of these other markets around the world, but SNM is a completely different animal.
